ISR Immune System Regulation Holding AB (publ) (5JK)
XFRA XFRA Primary 
SGX Summary
5JK Chart
ISR Immune System Regulation Holding AB (publ) (5JK) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
ISR Immune System Regulation Holding AB (publ) Profile
| - Industry | - Sector | Prof. Ola S. Winqvist M.D., Ph.D. CEO | XFRA Exchange | SE0008212195 ISIN |
| Sweden Country | 5 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
ISR Immune System Regulation Holding AB (publ) is a Swedish biotech company focused on the development of immunostimulatory drugs for the treatment of chronic infectious diseases and cancer. Founded in 2007, the company has dedicated itself to advancing medical science through its innovative research into the body’s immune response. With its headquarters located in Solna, Sweden, ISR Immune System Regulation Holding operates at the forefront of immunology and therapeutic research, aiming to provide novel solutions to some of the most challenging diseases facing humanity today.
Products and Services
- Covid-19 Vaccine
As part of its commitment to combating global health crises, ISR Immune System Regulation Holding AB (publ) is in the process of developing a vaccine against Covid-19. This vaccine is designed to harness the body's immune response to provide protection against the coronavirus, potentially reducing the incidence and severity of the disease.
- Hepatitis B (HBV) Drugs
ISR Immune System Regulation Holding AB (publ) is also developing therapeutic solutions for Hepatitis B, a serious liver infection caused by the hepatitis B virus (HBV). These drugs aim to stimulate the immune system to more effectively fight the virus, offering hope for a better standard of care for patients living with HBV.
- Human Immunodeficiency Virus (HIV) Treatments
The company's pipeline includes innovative treatments for Human Immunodeficiency Virus (HIV), focusing on immunostimulatory approaches to manage and potentially reduce the impact of this chronic disease. By targeting the immune response, these treatments endeavor to provide a novel means of improving the lives of those affected by HIV.
- Oncology Drugs
In the realm of cancer therapy, ISR Immune System Regulation Holding AB (publ) is pioneering the development of oncology drugs that leverage the power of the immune system. These drugs are designed to stimulate the body's natural defenses to recognize and combat cancer cells more effectively, representing a promising avenue in cancer treatment.
